metformin has been researched along with Cognitive Decline in 58 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Overweight/obese postmenopausal breast cancer survivors (n = 333) were randomized to a weight loss intervention versus control and metformin versus placebo in a 2 × 2 factorial design." | 9.30 | The effects of weight loss and metformin on cognition among breast cancer survivors: Evidence from the Reach for Health study. ( Hartman, SJ; Marinac, CR; Natarajan, L; Nelson, SH; Parker, BA; Patterson, RE, 2019) |
| " Metformin significantly reduced the occurrence of cognitive dysfunction in patients with T2D (HR 0." | 9.05 | Metformin therapy and cognitive dysfunction in patients with type 2 diabetes: A meta-analysis and systematic review. ( Ba, YG; Li, WS; Liu, Z; Zhang, HL; Zhang, QQ; Zhang, RX, 2020) |
| "To synthesize the best available evidence on the association of metformin-use with risk, progression, and severity of dementia." | 8.98 | Metformin Use Associated with Reduced Risk of Dementia in Patients with Diabetes: A Systematic Review and Meta-Analysis. ( Aromataris, E; Bellman, SM; Campbell, JM; Chapman, I; de Courten, B; Stephenson, MD, 2018) |
| "To assess whether the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin improves cognitive impairment in frail older adults with diabetes and heart failure with preserved ejection fraction (HFpEF)." | 8.12 | Empagliflozin Improves Cognitive Impairment in Frail Older Adults With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction. ( Frullone, S; Gambardella, J; Lombardi, A; Macina, G; Mone, P; Morgante, M; Pansini, A; Santulli, G, 2022) |
| " The present study has been designed to evaluate the neuroprotective effect of telmisartan and metformin on diazepam-induced cognitive dysfunction in mice." | 8.02 | Evaluation of nootropic activity of telmisartan and metformin on diazepam-induced cognitive dysfunction in mice through AMPK pathway and amelioration of hippocampal morphological alterations. ( Alfuraih, BS; Alsuhaibani, NA; Elsayed, AM; Mahmoud, RH; Nadwa, EH; Rashed, LA; Said, ES, 2021) |
| "To investigate the protective effects of metformin on the diabetic mice with cognitive impairment induced by the combination of streptozotocin (STZ) and isoflurane anesthesia." | 8.02 | Metformin improves cognitive impairment in diabetic mice induced by a combination of streptozotocin and isoflurane anesthesia. ( Li, P; Lv, Z; Zhang, J; Zhang, W; Zhao, L, 2021) |
| "These findings highlight a novel pathogenic mechanism of sepsis-related cognitive impairment through activation of inflammatory factors, and these are blocked by metformin to attenuate sepsis-induced neuronal injury and cognitive impairment." | 8.02 | Metformin attenuates sepsis-induced neuronal injury and cognitive impairment. ( Guo, C; Qin, Z; Xiao, X; Zhou, C, 2021) |
| "During pregnancy, mice were fed with a high-fat diet (GDM group) or a low-fat diet (Control group), and a third group received metformin while receiving a high-fat diet (Treatment group)." | 7.96 | Metformin administration during pregnancy attenuated the long-term maternal metabolic and cognitive impairments in a mouse model of gestational diabetes. ( Baker, PN; Chen, X; Han, TL; Qi, H; Wang, A; Yu, X; Zhang, H; Zhao, X; Zhao, Y; Zhou, X, 2020) |
| "According to the data obtained, methamphetamine caused significant depression, anxiety, motor activity disturbances and cognition impairment in experimental animals." | 7.91 | Protective role of metformin against methamphetamine induced anxiety, depression, cognition impairment and neurodegeneration in rat: The role of CREB/BDNF and Akt/GSK3 signaling pathways. ( Karami, L; Kermanshahi, S; Keshavarzi, S; Motaghinejad, M; Motevalian, M; Sadr, S, 2019) |
| "To determine the impact of hyperglycemia and metformin use on relevant B vitamin biomarkers and cognitive outcomes in older adults." | 7.91 | Hyperglycemia and Metformin Use Are Associated With B Vitamin Deficiency and Cognitive Dysfunction in Older Adults. ( Casey, MC; Cunningham, C; Gallagher, AM; Hoey, L; Hughes, CF; Laird, E; McCann, A; McCarroll, K; McNulty, H; Molloy, AM; O'Kane, M; Porter, KM; Strain, S; Tracey, F; Ward, M, 2019) |
| " Metformin, widely known as an antidiabetic drug, has been found to enhance spatial memory formation and improve anxiety-like behaviors in rodents." | 7.91 | Metformin reverses the schizophrenia-like behaviors induced by MK-801 in rats. ( Li, X; Liu, ZQ; Luo, C; Mao, XY; Wang, X; Yin, JY; Zhang, W; Zhou, HH, 2019) |
| "Metformin pretreatment before anesthesia enhanced cognitive performance in the novel object test." | 5.72 | Metformin alleviates prolonged isoflurane inhalation induced cognitive decline via reducing neuroinflammation in adult mice. ( Fang, X; Gu, X; Liu, S; Peng, L; Xia, T; Xie, W; Xu, J, 2022) |
| " Methods and Results The Diabetes Prevention Program was a randomized controlled trial comparing an intensive lifestyle intervention, metformin, or placebo for prevention of type 2 diabetes among patients with prediabetes." | 5.69 | Coronary Artery Calcium and Cognitive Decline in the Diabetes Prevention Program Outcomes Study. ( Crandall, JP; Dabelea, D; Gadde, KM; Goldberg, RB; Ibebuogu, UN; Luchsinger, JA; Orchard, TJ; Pi-Sunyer, FX; Schlögl, M; Temprosa, M; Watson, KE; Yin, X, 2023) |
| "Overweight/obese postmenopausal breast cancer survivors (n = 333) were randomized to a weight loss intervention versus control and metformin versus placebo in a 2 × 2 factorial design." | 5.30 | The effects of weight loss and metformin on cognition among breast cancer survivors: Evidence from the Reach for Health study. ( Hartman, SJ; Marinac, CR; Natarajan, L; Nelson, SH; Parker, BA; Patterson, RE, 2019) |
| " Metformin significantly reduced the occurrence of cognitive dysfunction in patients with T2D (HR 0." | 5.05 | Metformin therapy and cognitive dysfunction in patients with type 2 diabetes: A meta-analysis and systematic review. ( Ba, YG; Li, WS; Liu, Z; Zhang, HL; Zhang, QQ; Zhang, RX, 2020) |
| "To synthesize the best available evidence on the association of metformin-use with risk, progression, and severity of dementia." | 4.98 | Metformin Use Associated with Reduced Risk of Dementia in Patients with Diabetes: A Systematic Review and Meta-Analysis. ( Aromataris, E; Bellman, SM; Campbell, JM; Chapman, I; de Courten, B; Stephenson, MD, 2018) |
| " In this study, we assessed the intervention effect of metformin (MET) on cognitive dysfunction in mice induced by B[a]P from the perspective of glucolipid metabolism." | 4.31 | Metformin alleviates the cognitive impairment induced by benzo[a]pyrene via glucolipid metabolism regulated by FTO/FoxO6 pathway in mice. ( Li, Y; Miao, H; Song, Z; Xia, N; Zhang, H; Zhang, Z; Zhao, T, 2023) |
| "To assess whether the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin improves cognitive impairment in frail older adults with diabetes and heart failure with preserved ejection fraction (HFpEF)." | 4.12 | Empagliflozin Improves Cognitive Impairment in Frail Older Adults With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction. ( Frullone, S; Gambardella, J; Lombardi, A; Macina, G; Mone, P; Morgante, M; Pansini, A; Santulli, G, 2022) |
| " The present study has been designed to evaluate the neuroprotective effect of telmisartan and metformin on diazepam-induced cognitive dysfunction in mice." | 4.02 | Evaluation of nootropic activity of telmisartan and metformin on diazepam-induced cognitive dysfunction in mice through AMPK pathway and amelioration of hippocampal morphological alterations. ( Alfuraih, BS; Alsuhaibani, NA; Elsayed, AM; Mahmoud, RH; Nadwa, EH; Rashed, LA; Said, ES, 2021) |
| "To investigate the protective effects of metformin on the diabetic mice with cognitive impairment induced by the combination of streptozotocin (STZ) and isoflurane anesthesia." | 4.02 | Metformin improves cognitive impairment in diabetic mice induced by a combination of streptozotocin and isoflurane anesthesia. ( Li, P; Lv, Z; Zhang, J; Zhang, W; Zhao, L, 2021) |
| "These findings highlight a novel pathogenic mechanism of sepsis-related cognitive impairment through activation of inflammatory factors, and these are blocked by metformin to attenuate sepsis-induced neuronal injury and cognitive impairment." | 4.02 | Metformin attenuates sepsis-induced neuronal injury and cognitive impairment. ( Guo, C; Qin, Z; Xiao, X; Zhou, C, 2021) |
| "Sixty-two obese patients in treatment with metformin-with prediabetes (n = 41) or newly diagnosed T2DM (n = 21), were studied." | 4.02 | Insulin resistance and NAFLD may influence memory performance in obese patients with prediabetes or newly-diagnosed type 2 diabetes. ( Ciotti, S; Cipollone, F; Consoli, A; Desideri, G; Di Castelnuovo, A; Guagnano, MT; Liani, R; Santilli, F; Simeone, PG; Tartaro, A; Tripaldi, R; Vadini, F, 2021) |
| "During pregnancy, mice were fed with a high-fat diet (GDM group) or a low-fat diet (Control group), and a third group received metformin while receiving a high-fat diet (Treatment group)." | 3.96 | Metformin administration during pregnancy attenuated the long-term maternal metabolic and cognitive impairments in a mouse model of gestational diabetes. ( Baker, PN; Chen, X; Han, TL; Qi, H; Wang, A; Yu, X; Zhang, H; Zhao, X; Zhao, Y; Zhou, X, 2020) |
| "According to the data obtained, methamphetamine caused significant depression, anxiety, motor activity disturbances and cognition impairment in experimental animals." | 3.91 | Protective role of metformin against methamphetamine induced anxiety, depression, cognition impairment and neurodegeneration in rat: The role of CREB/BDNF and Akt/GSK3 signaling pathways. ( Karami, L; Kermanshahi, S; Keshavarzi, S; Motaghinejad, M; Motevalian, M; Sadr, S, 2019) |
| "To determine the impact of hyperglycemia and metformin use on relevant B vitamin biomarkers and cognitive outcomes in older adults." | 3.91 | Hyperglycemia and Metformin Use Are Associated With B Vitamin Deficiency and Cognitive Dysfunction in Older Adults. ( Casey, MC; Cunningham, C; Gallagher, AM; Hoey, L; Hughes, CF; Laird, E; McCann, A; McCarroll, K; McNulty, H; Molloy, AM; O'Kane, M; Porter, KM; Strain, S; Tracey, F; Ward, M, 2019) |
| " Metformin, widely known as an antidiabetic drug, has been found to enhance spatial memory formation and improve anxiety-like behaviors in rodents." | 3.91 | Metformin reverses the schizophrenia-like behaviors induced by MK-801 in rats. ( Li, X; Liu, ZQ; Luo, C; Mao, XY; Wang, X; Yin, JY; Zhang, W; Zhou, HH, 2019) |
| "Our results indicate that one of the most commonly used antidiabetic drug, metformin, has the potential to prevent the development of dementia and be a novel therapeutic drug for the amelioration of cognitive dysfunction in AD." | 3.91 | The protective effect of metformin in scopolamine-induced learning and memory impairment in rats. ( Aksit, D; Aksit, H; Aksoz, E; Gocmez, SS; Sahin, TD; Utkan, T, 2019) |
| "Large numbers of people with type 2 diabetes are obese." | 2.90 | Olfactory Dysfunction Mediates Adiposity in Cognitive Impairment of Type 2 Diabetes: Insights From Clinical and Functional Neuroimaging Studies. ( Bi, Y; Qing, Z; Wang, X; Yang, QX; Zhang, B; Zhang, W; Zhang, X; Zhang, Z; Zhu, D, 2019) |
| "Metformin users were 374 individuals, and 57 subjects didn't use metformin." | 1.91 | Assessment of cognitive impairment and depressive signs in patients with type 2 diabetes treated with metformin from Southeast Mexico: A cross-sectional study. ( Cruz-Castillo, JD; Genis-Mendoza, AD; González-Castro, TB; Hernández-Palacios, F; Juárez-Rojop, IE; Molina-Guzmán, G; Nolasco-Rosales, GA; Pérez-Osorio, DA; Rodríguez-Sánchez, E; Tovilla-Zárate, CA; Villar-Juárez, GE, 2023) |
| "Metformin pretreatment before anesthesia enhanced cognitive performance in the novel object test." | 1.72 | Metformin alleviates prolonged isoflurane inhalation induced cognitive decline via reducing neuroinflammation in adult mice. ( Fang, X; Gu, X; Liu, S; Peng, L; Xia, T; Xie, W; Xu, J, 2022) |
| "Berberine has been shown to promising effect for IR in vitro and in vivo." | 1.62 | Berberine ameliorates neuronal AD-like change via activating Pi3k/PGCε pathway. ( Bao, Y; Chen, Q; Han, Y; Liu, C; Liu, W; Liu, X; Wang, J; Wu, N; Ye, Y; Yu, Y, 2021) |
| "Metformin has been shown to expand the endogenous neural stem cell (NSC) pool and promote neurogenesis under physiological conditions and in response to neonatal brain injury, suggesting a potential role in neurorepair." | 1.62 | Metformin pretreatment rescues olfactory memory associated with subependymal zone neurogenesis in a juvenile model of cranial irradiation. ( Derkach, D; Heidari, M; Kehtari, T; Lakshman, N; Morshead, CM; Renaud, M, 2021) |
| "Similarly, hyperglycemia is known to impair endothelial function and is a predictor of severe cardiovascular outcomes, independent of the presence of diabetes." | 1.62 | Cognitive Impairment in Frail Hypertensive Elderly Patients: Role of Hyperglycemia. ( Boccalone, E; de Donato, A; Frullone, S; Gambardella, J; Martinelli, G; Matarese, A; Mone, P; Pansini, A; Santulli, G, 2021) |
| "Metformin treatment was not associated with changes of any of Korean version of the Consortium to Establish a Registry for Alzheimer's Diseases Assessment component scores or activities of daily living index." | 1.51 | Taking metformin and cognitive function change in older patients with diabetes. ( Kim, LK; Koo, BK; Lee, JY; Moon, MK, 2019) |
| "Metformin-treated mice revealed increased expression of lipogenic genes, i." | 1.51 | Metformin Therapy Aggravates Neurodegenerative Processes in ApoE-/- Mice. ( Brichmann, E; Kuhla, A; Meuth, L; Rühlmann, C; Thiele, R; Vollmar, B, 2019) |
| "Thus, to understand the cognitive impairments caused by this chemotherapeutic agent, a clinically relevant dose to cancer treatment was used in mice to establish the chemobrain models, and the spatial memory of these mice was assessed using multiple behavior tests." | 1.51 | Ameliorative effect of metformin on cyclophosphamide-induced memory impairment in mice. ( Alhowail, AH; Chigurupati, S; Mani, V; Sajid, S, 2019) |
| "Metformin was associated with an increased risk of MCI (subhazard ratio (SHR) = 2." | 1.48 | Association of antidiabetic medication use, cognitive decline, and risk of cognitive impairment in older people with type 2 diabetes: Results from the population-based Mayo Clinic Study of Aging. ( Edwards, K; Hagen, CE; Knopman, DS; Machulda, MM; Mielke, MM; Petersen, RC; Roberts, RO; Wennberg, AMV, 2018) |
| "Older adults with type 2 diabetes have an increased risk for mild and severe cognitive impairment probably as consequence of chronic hyperglycemia or fasting plasma glucose levels." | 1.40 | Dipeptidyl peptidase-4 inhibitors have protective effect on cognitive impairment in aged diabetic patients with mild cognitive impairment. ( Angellotti, E; Barbieri, M; Boccardi, V; Marfella, R; Paolisso, G; Rizzo, MR, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 17 (29.31) | 24.3611 |
| 2020's | 41 (70.69) | 2.80 |
| Authors | Studies |
|---|---|
| Said, ES | 1 |
| Elsayed, AM | 1 |
| Rashed, LA | 1 |
| Nadwa, EH | 1 |
| Alsuhaibani, NA | 1 |
| Alfuraih, BS | 1 |
| Mahmoud, RH | 1 |
| Wen, H | 1 |
| Tian, H | 1 |
| Liu, C | 2 |
| Zhang, X | 2 |
| Peng, Y | 1 |
| Yang, X | 1 |
| Chen, F | 1 |
| Li, J | 1 |
| Oo, TT | 1 |
| Sumneang, N | 1 |
| Ongnok, B | 4 |
| Arunsak, B | 2 |
| Chunchai, T | 5 |
| Kerdphoo, S | 1 |
| Apaijai, N | 2 |
| Pratchayasakul, W | 3 |
| Liang, G | 1 |
| Chattipakorn, N | 6 |
| Chattipakorn, SC | 6 |
| Zhou, C | 2 |
| Peng, B | 1 |
| Qin, Z | 2 |
| Zhu, W | 1 |
| Guo, C | 2 |
| Zhang, W | 3 |
| Zhao, L | 1 |
| Zhang, J | 1 |
| Li, P | 1 |
| Lv, Z | 1 |
| Xiao, X | 1 |
| Alhowail, AH | 2 |
| Almogbel, YS | 1 |
| Abdellatif, AAH | 1 |
| Aldubayan, MA | 1 |
| Almami, IS | 1 |
| Xiao, Y | 1 |
| Li, K | 1 |
| Bian, J | 1 |
| Liu, H | 1 |
| Zhai, X | 1 |
| El-Omar, E | 1 |
| Han, L | 1 |
| Gong, L | 1 |
| Wang, M | 1 |
| Mone, P | 2 |
| Lombardi, A | 1 |
| Gambardella, J | 2 |
| Pansini, A | 2 |
| Macina, G | 1 |
| Morgante, M | 1 |
| Frullone, S | 2 |
| Santulli, G | 2 |
| Tabatabaei Malazy, O | 1 |
| Bandarian, F | 1 |
| Qorbani, M | 1 |
| Mohseni, S | 1 |
| Mirsadeghi, S | 1 |
| Peimani, M | 1 |
| Larijani, B | 1 |
| Antal, B | 1 |
| McMahon, LP | 1 |
| Sultan, SF | 1 |
| Lithen, A | 1 |
| Wexler, DJ | 1 |
| Dickerson, B | 1 |
| Ratai, EM | 1 |
| Mujica-Parodi, LR | 1 |
| Song, Y | 1 |
| Liu, Z | 2 |
| Zhu, X | 1 |
| Hao, C | 1 |
| Hao, W | 1 |
| Wu, S | 1 |
| Yang, J | 1 |
| Lu, X | 1 |
| Jin, C | 2 |
| Peng, L | 1 |
| Liu, S | 1 |
| Xu, J | 1 |
| Xie, W | 1 |
| Fang, X | 1 |
| Xia, T | 1 |
| Gu, X | 1 |
| Nabizadeh, F | 1 |
| Kankam, SB | 1 |
| Balabandian, M | 1 |
| Hashemi, SM | 1 |
| Sharifkazemi, H | 1 |
| Rostami, MR | 1 |
| Nguyen, B | 1 |
| Deardorff, WJ | 1 |
| Shi, Y | 1 |
| Jing, B | 1 |
| Lee, AK | 1 |
| Lee, SJ | 1 |
| Pintana, H | 3 |
| Arinno, A | 3 |
| Pantiya, P | 3 |
| Khuanjing, T | 3 |
| Prathumsap, N | 3 |
| Maneechote, C | 3 |
| Khaleghi-Mehr, M | 1 |
| Delshad, AA | 1 |
| Shafie-Damavandi, S | 1 |
| Roghani, M | 1 |
| Nolasco-Rosales, GA | 1 |
| Villar-Juárez, GE | 1 |
| Pérez-Osorio, DA | 1 |
| Cruz-Castillo, JD | 1 |
| Molina-Guzmán, G | 1 |
| González-Castro, TB | 1 |
| Tovilla-Zárate, CA | 1 |
| Rodríguez-Sánchez, E | 1 |
| Genis-Mendoza, AD | 1 |
| Hernández-Palacios, F | 1 |
| Juárez-Rojop, IE | 1 |
| Zhao, T | 1 |
| Miao, H | 1 |
| Song, Z | 1 |
| Li, Y | 2 |
| Xia, N | 1 |
| Zhang, Z | 2 |
| Zhang, H | 3 |
| He, Y | 1 |
| Li, Z | 1 |
| Shi, X | 1 |
| Ding, J | 1 |
| Wang, X | 4 |
| Gadde, KM | 1 |
| Yin, X | 1 |
| Goldberg, RB | 1 |
| Orchard, TJ | 1 |
| Schlögl, M | 1 |
| Dabelea, D | 1 |
| Ibebuogu, UN | 1 |
| Watson, KE | 1 |
| Pi-Sunyer, FX | 1 |
| Crandall, JP | 1 |
| Temprosa, M | 1 |
| Luchsinger, JA | 2 |
| Sood, A | 1 |
| Capuano, AW | 1 |
| Wilson, RS | 1 |
| Barnes, LL | 1 |
| Kapasi, A | 1 |
| Bennett, DA | 1 |
| Arvanitakis, Z | 1 |
| Chigurupati, S | 1 |
| Sajid, S | 1 |
| Mani, V | 2 |
| Mohamed, MAE | 1 |
| Abdel-Rahman, RF | 1 |
| Mahmoud, SS | 1 |
| Khattab, MM | 1 |
| Safar, MM | 1 |
| Zhang, QQ | 1 |
| Li, WS | 1 |
| Zhang, HL | 1 |
| Ba, YG | 1 |
| Zhang, RX | 1 |
| Jinawong, K | 2 |
| Wongsuchai, S | 1 |
| Liu, B | 1 |
| Huang, B | 1 |
| Liu, J | 1 |
| Shi, JS | 1 |
| Zhao, Y | 1 |
| Zhou, X | 2 |
| Zhao, X | 1 |
| Yu, X | 2 |
| Wang, A | 1 |
| Chen, X | 1 |
| Qi, H | 1 |
| Han, TL | 1 |
| Baker, PN | 1 |
| Ayoub, R | 1 |
| Ruddy, RM | 1 |
| Cox, E | 1 |
| Oyefiade, A | 1 |
| Derkach, D | 2 |
| Laughlin, S | 1 |
| Ades-Aron, B | 1 |
| Shirzadi, Z | 1 |
| Fieremans, E | 1 |
| MacIntosh, BJ | 2 |
| de Medeiros, CB | 1 |
| Skocic, J | 1 |
| Bouffet, E | 1 |
| Miller, FD | 1 |
| Morshead, CM | 2 |
| Mabbott, DJ | 1 |
| Gibson, EM | 1 |
| Monje, M | 1 |
| Wu, CY | 1 |
| Ouk, M | 1 |
| Wong, YY | 1 |
| Anita, NZ | 1 |
| Edwards, JD | 1 |
| Yang, P | 1 |
| Shah, BR | 1 |
| Herrmann, N | 1 |
| Lanctôt, KL | 1 |
| Kapral, MK | 1 |
| Rabin, JS | 1 |
| Black, SE | 1 |
| Swardfager, W | 1 |
| Pongkan, W | 1 |
| Jaiwongkam, T | 1 |
| Tokuda, M | 1 |
| Wu, N | 1 |
| Liu, W | 1 |
| Wang, J | 1 |
| Han, Y | 1 |
| Ye, Y | 1 |
| Liu, X | 2 |
| Yu, Y | 1 |
| Chen, Q | 1 |
| Bao, Y | 1 |
| Violante-Cumpa, JR | 1 |
| Pérez-Arredondo, LA | 1 |
| González-González, JG | 1 |
| Mancillas-Adame, LG | 1 |
| Samaras, K | 1 |
| Crawford, JD | 1 |
| Draper, B | 1 |
| Trollor, JN | 1 |
| Brodaty, H | 1 |
| Sachdev, PS | 1 |
| Kehtari, T | 1 |
| Renaud, M | 1 |
| Heidari, M | 1 |
| Lakshman, N | 1 |
| Gorgich, EAC | 1 |
| Parsaie, H | 1 |
| Yarmand, S | 1 |
| Baharvand, F | 1 |
| Sarbishegi, M | 1 |
| Zhang, JH | 1 |
| Zhang, JF | 1 |
| Song, J | 1 |
| Bai, Y | 1 |
| Deng, L | 1 |
| Feng, CP | 1 |
| Xu, XY | 1 |
| Guo, HX | 1 |
| Wang, Y | 1 |
| Gao, X | 1 |
| Gu, Y | 1 |
| Zheng, JF | 1 |
| Zhen, Z | 1 |
| Su, H | 1 |
| Alharbi, I | 1 |
| Alhowail, A | 1 |
| Aldubayan, M | 1 |
| Almogbel, Y | 1 |
| Felemban, S | 1 |
| Alharbi, H | 1 |
| Vadini, F | 1 |
| Simeone, PG | 1 |
| Desideri, G | 1 |
| Liani, R | 1 |
| Tripaldi, R | 1 |
| Ciotti, S | 1 |
| Tartaro, A | 1 |
| Guagnano, MT | 1 |
| Di Castelnuovo, A | 1 |
| Cipollone, F | 1 |
| Consoli, A | 1 |
| Santilli, F | 1 |
| Li, Q | 2 |
| Jia, M | 1 |
| Yan, Z | 1 |
| Sun, F | 1 |
| He, C | 1 |
| Bu, X | 1 |
| Gao, P | 1 |
| He, H | 1 |
| Zhao, Z | 1 |
| Zhu, Z | 1 |
| de Donato, A | 1 |
| Martinelli, G | 1 |
| Boccalone, E | 1 |
| Matarese, A | 1 |
| Wennberg, AMV | 1 |
| Hagen, CE | 1 |
| Edwards, K | 1 |
| Roberts, RO | 1 |
| Machulda, MM | 1 |
| Knopman, DS | 1 |
| Petersen, RC | 1 |
| Mielke, MM | 1 |
| Campbell, JM | 1 |
| Stephenson, MD | 1 |
| de Courten, B | 1 |
| Chapman, I | 1 |
| Bellman, SM | 1 |
| Aromataris, E | 1 |
| Cukierman-Yaffe, T | 1 |
| Bosch, J | 1 |
| Jung, H | 1 |
| Punthakee, Z | 1 |
| Gerstein, HC | 1 |
| Keshavarzi, S | 1 |
| Kermanshahi, S | 1 |
| Karami, L | 1 |
| Motaghinejad, M | 1 |
| Motevalian, M | 1 |
| Sadr, S | 1 |
| Kuhla, A | 1 |
| Brichmann, E | 1 |
| Rühlmann, C | 1 |
| Thiele, R | 1 |
| Meuth, L | 1 |
| Vollmar, B | 1 |
| Porter, KM | 1 |
| Ward, M | 1 |
| Hughes, CF | 1 |
| O'Kane, M | 1 |
| Hoey, L | 1 |
| McCann, A | 1 |
| Molloy, AM | 1 |
| Cunningham, C | 1 |
| Casey, MC | 1 |
| Tracey, F | 1 |
| Strain, S | 1 |
| McCarroll, K | 1 |
| Laird, E | 1 |
| Gallagher, AM | 1 |
| McNulty, H | 1 |
| Koo, BK | 1 |
| Kim, LK | 1 |
| Lee, JY | 1 |
| Moon, MK | 1 |
| Luo, C | 1 |
| Mao, XY | 1 |
| Li, X | 1 |
| Yin, JY | 1 |
| Zhou, HH | 1 |
| Liu, ZQ | 1 |
| Hartman, SJ | 1 |
| Nelson, SH | 1 |
| Marinac, CR | 1 |
| Natarajan, L | 1 |
| Parker, BA | 1 |
| Patterson, RE | 1 |
| Zhang, B | 1 |
| Yang, QX | 1 |
| Qing, Z | 1 |
| Zhu, D | 1 |
| Bi, Y | 1 |
| Aksoz, E | 1 |
| Gocmez, SS | 1 |
| Sahin, TD | 1 |
| Aksit, D | 1 |
| Aksit, H | 1 |
| Utkan, T | 1 |
| Rizzo, MR | 1 |
| Barbieri, M | 1 |
| Boccardi, V | 1 |
| Angellotti, E | 1 |
| Marfella, R | 1 |
| Paolisso, G | 1 |
| Perez, T | 1 |
| Chang, H | 1 |
| Mehta, P | 1 |
| Steffener, J | 1 |
| Pradabhan, G | 1 |
| Ichise, M | 1 |
| Manly, J | 1 |
| Devanand, DP | 1 |
| Bagiella, E | 1 |
| Liccini, A | 1 |
| Malmstrom, TK | 1 |
| Morley, JE | 1 |
| Qi, B | 1 |
| Hu, L | 1 |
| Zhu, L | 1 |
| Shang, L | 1 |
| Sheng, L | 1 |
| Liu, N | 1 |
| Wen, N | 1 |
| Wang, Q | 1 |
| Yang, Y | 1 |
| Ashabi, G | 1 |
| Sarkaki, A | 1 |
| Khodagholi, F | 1 |
| Zareh Shahamati, S | 1 |
| Goudarzvand, M | 1 |
| Farbood, Y | 1 |
| Badavi, M | 1 |
| Khalaj, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Cognitive and Physical Impairment in Frail Older Adults[NCT04962841] | 485 participants (Anticipated) | Observational | 2020-04-01 | Recruiting | |||
| Drug Repurposing Using Metformin for Improving the Therapeutic Outcome in Multiple Sclerosis Patients[NCT05298670] | Phase 2 | 80 participants (Anticipated) | Interventional | 2022-02-01 | Recruiting | ||
| Placebo Controlled Double Blind Crossover Trial of Metformin for Brain Repair in Children With Cranial-Spinal Radiation for Medulloblastoma[NCT02040376] | Phase 3 | 24 participants (Actual) | Interventional | 2014-06-13 | Completed | ||
| Effects of Liraglutide on the Cognitive Function in Patients With Type 2 Diabetes Mellitus[NCT03707171] | Phase 3 | 30 participants (Actual) | Interventional | 2018-10-01 | Completed | ||
| A Multicenter, International Randomized, 2x2 Factorial Design Study to Evaluate the Effects of Lantus (Insulin Glargine) Versus Standard Care, and of Omega-3 Fatty Acids Versus Placebo, in Reducing Cardiovascular Morbidity and Mortality in High Risk Peopl[NCT00069784] | Phase 3 | 12,537 participants (Actual) | Interventional | 2003-08-31 | Completed | ||
| A Multi-center, Prospective, Cohort Study to Elucidate the Effects of Metformin Treatment on Steroid Hormones and Social Behavior. Linking Autistic Behaviorial Symptoms to Changes in Steroid Hormone Availability[NCT04930471] | 45 participants (Anticipated) | Observational | 2021-06-30 | Not yet recruiting | |||
| A Prospective, Randomized, Open Label, Parallel, 12-month Study to Explore and Evaluate the Therapeutic Effects ofLiraglutide, Empagliflozin and Linagliptin on the Cognitive Function, Olfactory Function, and Odor-induced Brain Activation in T2DM Patients [NCT05313529] | 324 participants (Anticipated) | Interventional | 2022-10-08 | Recruiting | |||
| A Prospective, Randomized, Open Label, Parallel, 6-month Study to Explore and Evaluate the Therapeutic Effects of Henagliflozin on the Cognitive Function, Olfactory Function, and Odor-induced Brain Activation in T2DM Patients With Mild Cognitive Impairmen[NCT06085703] | 60 participants (Anticipated) | Interventional | 2023-09-01 | Recruiting | |||
| The Cross-sectional and Longitudinal Study of Relationship Between Diabetes and Cognitive Impairment by Olfactory Function Assessment and Functional MRI in Obese and Normal Weight Diabetic Patients[NCT02738671] | 250 participants (Actual) | Observational | 2016-01-31 | Completed | |||
| Early Diagnosis and Risk Evaluation of Mild Cognitive Impairment in Diabetes[NCT05590442] | 500 participants (Anticipated) | Observational | 2022-09-01 | Recruiting | |||
| Metformin in the Prevention of Alzheimer's Disease[NCT00620191] | Phase 2 | 80 participants (Actual) | Interventional | 2008-06-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The incidence was determined by calculating the proportion of randomized participants without diabetes at randomization who either developed diabetes during the study or who were classified as having possible diabetes based on results of two oral glucose tolerance tests (OGTT) performed after the last follow-up visit (within 21-28 days for OGTT#1 and within 10-14 weeks for OGTT#2). (NCT00069784)
Timeframe: from randomization until the last follow-up visit or last OGTT (median duration of follow-up: 6.2 years)
| Intervention | percentage of patients (Number) |
|---|---|
| Insulin Glargine | 24.7 |
| Standard Care | 31.2 |
Data on cancers that occurred in association with hospitalizations were collected systematically in both groups from the start of the study. All reported cancers occurring during the trial (new or recurrent) were adjudicated by the Event Adjudication Committee. (NCT00069784)
Timeframe: from randomization until study cut-off date (median duration of follow-up: 6.2 years)
| Intervention | participants (Number) |
|---|---|
| Insulin Glargine | 559 |
| Standard Care | 561 |
Number of deaths due to any cause (NCT00069784)
Timeframe: from randomization until study cut-off date (median duration of follow-up: 6.2 years)
| Intervention | participants (Number) |
|---|---|
| Insulin Glargine | 951 |
| Standard Care | 965 |
"The composite outcome used to analyze microvascular disease progression contained components of clinical events:~the occurrence of laser surgery or vitrectomy for diabetic retinopathy (DR);~the development of blindness due to DR;~the occurrence of renal death or renal replacement therapy; as well as the following laboratory-based events:~doubling of serum creatinine; or~progression of albuminuria (from none to microalbuminuria [at least 30 mg/g creatinine], to macroalbuminuria [at least 300 mg/g creatinine])." (NCT00069784)
Timeframe: from randomization until study cut-off date (median duration of follow-up: 6.2 years)
| Intervention | participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Participants with a composite endpoint | Endpoint's composition: vitrectomy | Endpoint's composition: laser therapy for DR | Endpoint's composition: dialysis | Endpoint's composition: renal transplant | Endpoint's composition: serum creatinine doubled | Endpoint's composition: death due to renal failure | Endpoint's composition: albuminuria progression | |
| Insulin Glargine | 1323 | 24 | 57 | 18 | 0 | 82 | 4 | 1153 |
| Standard Care | 1363 | 25 | 67 | 28 | 0 | 88 | 3 | 1171 |
"Number of participants with a first occurrence of one of the above events.~The outcome's evaluation is based on the number of such positively-adjudicated first events occurring for patients assigned to the study groups. Assessments of the above events were reviewed by the Event Adjudication Committee who was kept blinded to the group assignment of participants.~Statistical analysis is performed on the time from randomization to the first occurrence of the events. Number of participants with a composite endpoint (i.e. with first occurrence of CV death, nonfatal MI or nonfatal stroke) is provided in the first row of the statistical table." (NCT00069784)
Timeframe: from randomization until study cut-off date (median duration of follow-up: 6.2 years)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Participants with a composite endpoint | Endpoint's composition: CV death | Endpoint's composition: nonfatal MI | Endpoint's composition: nonfatal stroke | |
| Insulin Glargine | 1041 | 484 | 297 | 261 |
| Standard Care | 1013 | 476 | 282 | 256 |
"Number of participants with a first occurrence of one of the above events (revascularization procedures included coronary artery bypass graft, percutaneous transluminal coronary angioplasty (PTCA) i.e. balloon, PTCA with stent, other percutaneous intervention, carotid angioplasty with/without stent, carotid endarterectomy, peripheral angioplasty with or without stent, peripheral vascular surgery, and limb amputation due to vascular disease).~The outcome's evaluation is based on the number of such positively-adjudicated first events occurring for patients assigned to the study groups. Assessments of the above events were reviewed by the Event Adjudication Committee who was kept blinded to the group assignment of participants.~Statistical analysis is performed on the time from randomization to the first occurrence of the events. Number of participants with a composite endpoint (i.e. with first occurrence of the events) is provided in the first row of the statistical table." (NCT00069784)
Timeframe: from randomization until study cut-off date (median duration of follow-up: 6.2 years)
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Participants with a composite endpoint | Endpoint's composition: CV death | Endpoint's composition: nonfatal MI | Endpoint's composition: nonfatal stroke | Endpoint's composition: revascularization | Endpoint's composition: hospitalization for HF | |
| Insulin Glargine | 1792 | 350 | 257 | 231 | 763 | 249 |
| Standard Care | 1727 | 339 | 238 | 227 | 717 | 259 |
"Symptomatic hypoglycemia was defined as an event with clinical symptoms consistent with hypoglycemia, based on data recorded in the participant's diary. These were further categorized as confirmed (ie, with a concomitant home glucose reading ≤54 mg/dL [≤3.0 mmol/L]) or unconfirmed.~Severe hypoglycemia was defined as an event with clinical symptoms consistent with hypoglycemia in which the participant required the assistance of another person, and one of the following:~the event was associated with a documented self-measured or laboratory plasma glucose level ≤36 mg/dL (≤2.0 mmol/L), or~the event was associated with prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration." (NCT00069784)
Timeframe: on-treatment period (median duration of follow-up: 6.2 years)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Patients with hypoglycemia events | Patients with non-severe hypoglycemia | Patients with confirmed non-severe hypoglycemia | Patients with severe hypoglycemia | |
| Insulin Glargine | 3597 | 3533 | 2581 | 352 |
| Standard Care | 1624 | 1582 | 904 | 113 |
Change in plasma Amyloid beta-42 from baseline to 12 months (NCT00620191)
Timeframe: 12 months
| Intervention | pg/ml (Mean) |
|---|---|
| Placebo | -4.40 |
| Metformin | 0.69 |
Change in relative glucose uptake (rCMRgl) in the posterior cingulate-precuneus measured with subscale (ADAS-Cog) from brain [18]F-labeled 2-deoxy-2-fluoro-D-glucose (FDG) positron emission tomography (PET). The unit for rCMRgl is %. The results presented are absolute differences in rCMRgl, presented in % units; the change was calculated subtracting the baseline rCMRgl from the follow-up rCMRgl (NCT00620191)
Timeframe: 12 months
| Intervention | percentage of rCMRgl (Mean) |
|---|---|
| Placebo | 0.0 |
| Metformin | 2.0 |
The ADAS-cog is an aggregate for several cognitive tests intended to provide a global cognitive score and consists of 11 tasks. The tasks (and corresponding score range)) are Word Recall (0-10), Naming (0-4), Commands (0-5), Constructional Praxis (0-5) Ideational Praxis (0-5), Orientation (0-8), Word Recognition (0-12), Language (0-5), Word Finding Difficulty (0-5), and Remembering Test Instructions (1-5). The range of aggregate scores (sum of scores) is 1 to 69, with higher scores meaning worse cognitive performance. The change was calculated subtracting the baseline score from the final visit score. (NCT00620191)
Timeframe: 12 months
| Intervention | score (Mean) |
|---|---|
| Placebo | -1.98 |
| Metformin | 0.0 |
The Selective Reminding Test measures verbal learning and delayed recall through a multiple-trial list-learning paradigm. Patients are presented aurally with a list of 12 words for trial 1 and are asked to recall as many as possible. For trials 2-6, there is a selective presentation of only those words not recalled on the previous trial. Trial 7 is similar to the other trials but is assessed after an 11-minute delay. The score for the selective reminding test is the unweighted average of seven individual study results (min=0 and max=84) Higher scores indicate a better cognitive performance. The total recall score from the first visit was subtracted from that of the last visit to calculate the change in score (total words recalled). (NCT00620191)
Timeframe: 12 months
| Intervention | score on a scale (Mean) |
|---|---|
| Placebo | 5.7 |
| Metformin | 9.4 |
4 reviews available for metformin and Cognitive Decline
| Article | Year |
|---|---|
The effect of metformin on cognitive function: A systematic review and meta-analysis.
Topics: Alzheimer Disease; Cognition; Cognitive Dysfunction; Dementia; Disease Progression; Humans; Metformi | 2022 |
Type 2 diabetes mellitus accelerates brain aging and cognitive decline: Complementary findings from UK Biobank and meta-analyses.
Topics: Aged; Aged, 80 and over; Aging; Atrophy; Biological Specimen Banks; Cognitive Dysfunction; Cross-Sec | 2022 |
Metformin therapy and cognitive dysfunction in patients with type 2 diabetes: A meta-analysis and systematic review.
Topics: Cognitive Dysfunction; Diabetes Mellitus, Type 2; Humans; Metformin | 2020 |
Metformin Use Associated with Reduced Risk of Dementia in Patients with Diabetes: A Systematic Review and Meta-Analysis.
Topics: Cognitive Dysfunction; Dementia; Diabetes Mellitus; Disease Progression; Humans; Hypoglycemic Agents | 2018 |
7 trials available for metformin and Cognitive Decline
| Article | Year |
|---|---|
Coronary Artery Calcium and Cognitive Decline in the Diabetes Prevention Program Outcomes Study.
Topics: Adult; Calcinosis; Calcium; Calcium, Dietary; Cognitive Dysfunction; Coronary Artery Disease; Corona | 2023 |
Assessment of cognitive and neural recovery in survivors of pediatric brain tumors in a pilot clinical trial using metformin.
Topics: Adolescent; Adult; Brain; Brain Neoplasms; Cancer Survivors; Child; Child, Preschool; Cognition; Cog | 2020 |
Assessment of cognitive and neural recovery in survivors of pediatric brain tumors in a pilot clinical trial using metformin.
Topics: Adolescent; Adult; Brain; Brain Neoplasms; Cancer Survivors; Child; Child, Preschool; Cognition; Cog | 2020 |
Assessment of cognitive and neural recovery in survivors of pediatric brain tumors in a pilot clinical trial using metformin.
Topics: Adolescent; Adult; Brain; Brain Neoplasms; Cancer Survivors; Child; Child, Preschool; Cognition; Cog | 2020 |
Assessment of cognitive and neural recovery in survivors of pediatric brain tumors in a pilot clinical trial using metformin.
Topics: Adolescent; Adult; Brain; Brain Neoplasms; Cancer Survivors; Child; Child, Preschool; Cognition; Cog | 2020 |
Activation of Glucagon-Like Peptide-1 Receptor Ameliorates Cognitive Decline in Type 2 Diabetes Mellitus Through a Metabolism-Independent Pathway.
Topics: Biomarkers; Blood Glucose; Cognition; Cognitive Dysfunction; Diabetes Mellitus, Type 2; Female; Foll | 2021 |
Hypoglycemia and Incident Cognitive Dysfunction: A Post Hoc Analysis From the ORIGIN Trial.
Topics: Aged; Cardiovascular Diseases; Cognitive Dysfunction; Educational Status; Female; Humans; Hypoglycem | 2019 |
The effects of weight loss and metformin on cognition among breast cancer survivors: Evidence from the Reach for Health study.
Topics: Aged; Aged, 80 and over; Breast Neoplasms; Cancer Survivors; Cognitive Dysfunction; Combined Modalit | 2019 |
Olfactory Dysfunction Mediates Adiposity in Cognitive Impairment of Type 2 Diabetes: Insights From Clinical and Functional Neuroimaging Studies.
Topics: Adiposity; Adult; Aged; Blood Glucose; Brain; Cognition; Cognitive Dysfunction; Diabetes Mellitus, T | 2019 |
Olfactory Dysfunction Mediates Adiposity in Cognitive Impairment of Type 2 Diabetes: Insights From Clinical and Functional Neuroimaging Studies.
Topics: Adiposity; Adult; Aged; Blood Glucose; Brain; Cognition; Cognitive Dysfunction; Diabetes Mellitus, T | 2019 |
Olfactory Dysfunction Mediates Adiposity in Cognitive Impairment of Type 2 Diabetes: Insights From Clinical and Functional Neuroimaging Studies.
Topics: Adiposity; Adult; Aged; Blood Glucose; Brain; Cognition; Cognitive Dysfunction; Diabetes Mellitus, T | 2019 |
Olfactory Dysfunction Mediates Adiposity in Cognitive Impairment of Type 2 Diabetes: Insights From Clinical and Functional Neuroimaging Studies.
Topics: Adiposity; Adult; Aged; Blood Glucose; Brain; Cognition; Cognitive Dysfunction; Diabetes Mellitus, T | 2019 |
Olfactory Dysfunction Mediates Adiposity in Cognitive Impairment of Type 2 Diabetes: Insights From Clinical and Functional Neuroimaging Studies.
Topics: Adiposity; Adult; Aged; Blood Glucose; Brain; Cognition; Cognitive Dysfunction; Diabetes Mellitus, T | 2019 |
Olfactory Dysfunction Mediates Adiposity in Cognitive Impairment of Type 2 Diabetes: Insights From Clinical and Functional Neuroimaging Studies.
Topics: Adiposity; Adult; Aged; Blood Glucose; Brain; Cognition; Cognitive Dysfunction; Diabetes Mellitus, T | 2019 |
Olfactory Dysfunction Mediates Adiposity in Cognitive Impairment of Type 2 Diabetes: Insights From Clinical and Functional Neuroimaging Studies.
Topics: Adiposity; Adult; Aged; Blood Glucose; Brain; Cognition; Cognitive Dysfunction; Diabetes Mellitus, T | 2019 |
Olfactory Dysfunction Mediates Adiposity in Cognitive Impairment of Type 2 Diabetes: Insights From Clinical and Functional Neuroimaging Studies.
Topics: Adiposity; Adult; Aged; Blood Glucose; Brain; Cognition; Cognitive Dysfunction; Diabetes Mellitus, T | 2019 |
Olfactory Dysfunction Mediates Adiposity in Cognitive Impairment of Type 2 Diabetes: Insights From Clinical and Functional Neuroimaging Studies.
Topics: Adiposity; Adult; Aged; Blood Glucose; Brain; Cognition; Cognitive Dysfunction; Diabetes Mellitus, T | 2019 |
Olfactory Dysfunction Mediates Adiposity in Cognitive Impairment of Type 2 Diabetes: Insights From Clinical and Functional Neuroimaging Studies.
Topics: Adiposity; Adult; Aged; Blood Glucose; Brain; Cognition; Cognitive Dysfunction; Diabetes Mellitus, T | 2019 |
Olfactory Dysfunction Mediates Adiposity in Cognitive Impairment of Type 2 Diabetes: Insights From Clinical and Functional Neuroimaging Studies.
Topics: Adiposity; Adult; Aged; Blood Glucose; Brain; Cognition; Cognitive Dysfunction; Diabetes Mellitus, T | 2019 |
Olfactory Dysfunction Mediates Adiposity in Cognitive Impairment of Type 2 Diabetes: Insights From Clinical and Functional Neuroimaging Studies.
Topics: Adiposity; Adult; Aged; Blood Glucose; Brain; Cognition; Cognitive Dysfunction; Diabetes Mellitus, T | 2019 |
Olfactory Dysfunction Mediates Adiposity in Cognitive Impairment of Type 2 Diabetes: Insights From Clinical and Functional Neuroimaging Studies.
Topics: Adiposity; Adult; Aged; Blood Glucose; Brain; Cognition; Cognitive Dysfunction; Diabetes Mellitus, T | 2019 |
Olfactory Dysfunction Mediates Adiposity in Cognitive Impairment of Type 2 Diabetes: Insights From Clinical and Functional Neuroimaging Studies.
Topics: Adiposity; Adult; Aged; Blood Glucose; Brain; Cognition; Cognitive Dysfunction; Diabetes Mellitus, T | 2019 |
Olfactory Dysfunction Mediates Adiposity in Cognitive Impairment of Type 2 Diabetes: Insights From Clinical and Functional Neuroimaging Studies.
Topics: Adiposity; Adult; Aged; Blood Glucose; Brain; Cognition; Cognitive Dysfunction; Diabetes Mellitus, T | 2019 |
Olfactory Dysfunction Mediates Adiposity in Cognitive Impairment of Type 2 Diabetes: Insights From Clinical and Functional Neuroimaging Studies.
Topics: Adiposity; Adult; Aged; Blood Glucose; Brain; Cognition; Cognitive Dysfunction; Diabetes Mellitus, T | 2019 |
Metformin in Amnestic Mild Cognitive Impairment: Results of a Pilot Randomized Placebo Controlled Clinical Trial.
Topics: Aged; Aged, 80 and over; Amyloid beta-Peptides; Brain; Cognitive Dysfunction; Double-Blind Method; F | 2016 |
47 other studies available for metformin and Cognitive Decline
| Article | Year |
|---|---|
Evaluation of nootropic activity of telmisartan and metformin on diazepam-induced cognitive dysfunction in mice through AMPK pathway and amelioration of hippocampal morphological alterations.
Topics: AMP-Activated Protein Kinases; Animals; Behavior, Animal; Caspase 3; Cell Death; Cognitive Dysfuncti | 2021 |
Metformin and cyanidin 3-
Topics: Animals; Anthocyanins; Cognitive Dysfunction; Hypoglycemic Agents; Male; Metformin; Mice; Mice, Inbr | 2021 |
L6H21 protects against cognitive impairment and brain pathologies via toll-like receptor 4-myeloid differentiation factor 2 signalling in prediabetic rats.
Topics: Animals; Brain; Cognitive Dysfunction; Diet, High-Fat; Insulin Resistance; Male; Metformin; Prediabe | 2022 |
Metformin attenuates LPS-induced neuronal injury and cognitive impairments by blocking NF-κB pathway.
Topics: Animals; Cognition; Cognitive Dysfunction; Hippocampus; Inflammation; Lipopolysaccharides; Male; Met | 2021 |
Metformin improves cognitive impairment in diabetic mice induced by a combination of streptozotocin and isoflurane anesthesia.
Topics: Anesthesia; Animals; Cognitive Dysfunction; Diabetes Mellitus, Experimental; Disease Models, Animal; | 2021 |
Metformin attenuates sepsis-induced neuronal injury and cognitive impairment.
Topics: Animals; Brain; Cecum; Cognition; Cognition Disorders; Cognitive Dysfunction; Disease Models, Animal | 2021 |
Elucidating the mechanism underlying cognitive dysfunction by investigating the effects of CMF and MET treatment on hippocampal neurons.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cognitive Dysfunction; Cyclophosph | 2022 |
Urolithin A Attenuates Diabetes-Associated Cognitive Impairment by Ameliorating Intestinal Barrier Dysfunction via N-glycan Biosynthesis Pathway.
Topics: Animals; Cognitive Dysfunction; Coumarins; Diabetes Mellitus, Type 2; Diet, High-Fat; Inflammation; | 2022 |
Empagliflozin Improves Cognitive Impairment in Frail Older Adults With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction.
Topics: Aged; Benzhydryl Compounds; Cognitive Dysfunction; Diabetes Mellitus, Type 2; Frail Elderly; Glucosi | 2022 |
Metformin alleviates the cognitive impairment caused by aluminum by improving energy metabolism disorders in mice.
Topics: Aluminum; AMP-Activated Protein Kinases; Animals; Cognitive Dysfunction; Energy Metabolism; Glucose; | 2022 |
Metformin alleviates prolonged isoflurane inhalation induced cognitive decline via reducing neuroinflammation in adult mice.
Topics: Anesthetics; Animals; Cognitive Dysfunction; COVID-19; Isoflurane; Metformin; Mice; Microglia; Neuro | 2022 |
Metformin use and brain atrophy in nondemented elderly individuals with diabetes.
Topics: Aged; Alzheimer Disease; Atrophy; Brain; Cognitive Dysfunction; Diabetes Mellitus; Hippocampus; Huma | 2022 |
Fingerstick glucose monitoring by cognitive impairment status in Veterans Affairs nursing home residents with diabetes.
Topics: Aged; Blood Glucose; Blood Glucose Self-Monitoring; Cognitive Dysfunction; Diabetes Mellitus; Humans | 2022 |
Melatonin and metformin counteract cognitive dysfunction equally in male rats with doxorubicin-induced chemobrain.
Topics: Animals; Chemotherapy-Related Cognitive Impairment; Cognitive Dysfunction; Doxorubicin; Encephalitis | 2023 |
Melatonin and metformin counteract cognitive dysfunction equally in male rats with doxorubicin-induced chemobrain.
Topics: Animals; Chemotherapy-Related Cognitive Impairment; Cognitive Dysfunction; Doxorubicin; Encephalitis | 2023 |
Melatonin and metformin counteract cognitive dysfunction equally in male rats with doxorubicin-induced chemobrain.
Topics: Animals; Chemotherapy-Related Cognitive Impairment; Cognitive Dysfunction; Doxorubicin; Encephalitis | 2023 |
Melatonin and metformin counteract cognitive dysfunction equally in male rats with doxorubicin-induced chemobrain.
Topics: Animals; Chemotherapy-Related Cognitive Impairment; Cognitive Dysfunction; Doxorubicin; Encephalitis | 2023 |
Metformin mitigates amyloid β
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cognitive Dysfunction; Diabetes Mellitus, Type 2; | 2023 |
Assessment of cognitive impairment and depressive signs in patients with type 2 diabetes treated with metformin from Southeast Mexico: A cross-sectional study.
Topics: Adult; Aged; Antidepressive Agents; Cognitive Dysfunction; Cross-Sectional Studies; Diabetes Mellitu | 2023 |
Metformin alleviates the cognitive impairment induced by benzo[a]pyrene via glucolipid metabolism regulated by FTO/FoxO6 pathway in mice.
Topics: Alpha-Ketoglutarate-Dependent Dioxygenase FTO; Animals; Benzo(a)pyrene; Cognitive Dysfunction; Liver | 2023 |
Metformin attenuates white matter injury and cognitive impairment induced by chronic cerebral hypoperfusion.
Topics: Animals; Brain Ischemia; Carotid Stenosis; Cognitive Dysfunction; Dementia, Vascular; Diabetes Melli | 2023 |
Metformin, age-related cognitive decline, and brain pathology.
Topics: Alzheimer Disease; Brain; Cerebral Infarction; Cognition; Cognitive Dysfunction; Diabetes Mellitus; | 2024 |
Ameliorative effect of metformin on cyclophosphamide-induced memory impairment in mice.
Topics: Animals; Cognitive Dysfunction; Cyclophosphamide; Disease Models, Animal; Dose-Response Relationship | 2019 |
Metformin and trimetazidine ameliorate diabetes-induced cognitive impediment in status epileptic rats.
Topics: Administration, Oral; Animals; Cognitive Dysfunction; Diabetes Mellitus, Experimental; Hippocampus; | 2020 |
Necrostatin-1 Mitigates Cognitive Dysfunction in Prediabetic Rats With No Alteration in Insulin Sensitivity.
Topics: Animals; Cognitive Dysfunction; Diet, High-Fat; Hippocampus; Imidazoles; Indoles; Insulin Resistance | 2020 |
Dendrobium nobile Lindl alkaloid and metformin ameliorate cognitive dysfunction in senescence-accelerated mice via suppression of endoplasmic reticulum stress.
Topics: Aging; Alkaloids; Animals; Cognitive Dysfunction; Dendrobium; Dose-Response Relationship, Drug; Endo | 2020 |
Metformin administration during pregnancy attenuated the long-term maternal metabolic and cognitive impairments in a mouse model of gestational diabetes.
Topics: Animals; Cognitive Dysfunction; Diabetes, Gestational; Diet, Fat-Restricted; Diet, High-Fat; Female; | 2020 |
Treating cancer therapy-related cognitive impairment.
Topics: Brain Neoplasms; Child; Cognitive Dysfunction; Female; Humans; Male; Metformin; Neurons; Radiotherap | 2020 |
Relationships between memory decline and the use of metformin or DPP4 inhibitors in people with type 2 diabetes with normal cognition or Alzheimer's disease, and the role APOE carrier status.
Topics: Aged; Aging; Alzheimer Disease; Apolipoprotein E4; Apolipoproteins E; Cognition; Cognitive Dysfuncti | 2020 |
Not only metformin, but also D-allulose, alleviates metabolic disturbance and cognitive decline in prediabetic rats.
Topics: Animals; Cognitive Dysfunction; Diet, High-Fat; Drinking Water; Fructose; Insulin Resistance; Insuli | 2022 |
Berberine ameliorates neuronal AD-like change via activating Pi3k/PGCε pathway.
Topics: Amyloid beta-Peptides; Animals; Berberine; Cell Line, Tumor; Cognitive Dysfunction; Diabetes Mellitu | 2021 |
Comment on Samara et al. Metformin Use Is Associated With Slowed Cognitive Decline and Reduced Incident Dementia in Older Adults With Type 2 Diabetes: The Sydney Memory and Ageing Study. Diabetes Care 2020;43:2691-2701.
Topics: Aged; Aging; Cognitive Dysfunction; Dementia; Diabetes Mellitus, Type 2; Humans; Metformin | 2021 |
Response to Comment on Samara et al. Metformin Use Is Associated With Slowed Cognitive Decline and Reduced Incident Dementia in Older Adults With Type 2 Diabetes: The Sydney Memory and Ageing Study. Diabetes Care 2020;43:2691-2701.
Topics: Aged; Aging; Cognitive Dysfunction; Dementia; Diabetes Mellitus, Type 2; Humans; Metformin | 2021 |
Metformin pretreatment rescues olfactory memory associated with subependymal zone neurogenesis in a juvenile model of cranial irradiation.
Topics: Animals; Brain; Brain Injuries; Cognitive Dysfunction; Cranial Irradiation; Disease Models, Animal; | 2021 |
Long-term administration of metformin ameliorates age-dependent oxidative stress and cognitive function in rats.
Topics: Aging; Animals; Antioxidants; CA1 Region, Hippocampal; Cognitive Dysfunction; Male; Memory Disorders | 2021 |
Effects of Berberine on Diabetes and Cognitive Impairment in an Animal Model: The Mechanisms of Action.
Topics: Animals; Apoptosis; Berberine; Cognitive Dysfunction; Diabetes Mellitus, Experimental; Diet, High-Fa | 2021 |
DOX and MET treatment induces cognitive impairment through downregulation of IL-1-alpha and IRS-1 in the rat brain.
Topics: Animals; Antibiotics, Antineoplastic; Brain; Cognitive Dysfunction; Cytokines; Down-Regulation; Doxo | 2021 |
Insulin resistance and NAFLD may influence memory performance in obese patients with prediabetes or newly-diagnosed type 2 diabetes.
Topics: Age Factors; Blood Glucose; Cognition; Cognitive Dysfunction; Diabetes Mellitus, Type 2; Female; Hum | 2021 |
Cognitive Impairment in Frail Hypertensive Elderly Patients: Role of Hyperglycemia.
Topics: Aged; Cognitive Dysfunction; Endothelial Cells; Frail Elderly; Humans; Hyperglycemia; Hypertension; | 2021 |
Association of antidiabetic medication use, cognitive decline, and risk of cognitive impairment in older people with type 2 diabetes: Results from the population-based Mayo Clinic Study of Aging.
Topics: Aged; Aged, 80 and over; Body Mass Index; Cognition; Cognitive Dysfunction; Cross-Sectional Studies; | 2018 |
Protective role of metformin against methamphetamine induced anxiety, depression, cognition impairment and neurodegeneration in rat: The role of CREB/BDNF and Akt/GSK3 signaling pathways.
Topics: Animals; Anxiety; Brain-Derived Neurotrophic Factor; Central Nervous System Stimulants; Cognitive Dy | 2019 |
Metformin Therapy Aggravates Neurodegenerative Processes in ApoE-/- Mice.
Topics: Adenylate Kinase; Animals; Apolipoproteins E; Cognitive Dysfunction; Disease Models, Animal; Fibrobl | 2019 |
Hyperglycemia and Metformin Use Are Associated With B Vitamin Deficiency and Cognitive Dysfunction in Older Adults.
Topics: Aged; Aged, 80 and over; Cognitive Dysfunction; Cohort Studies; Female; Folic Acid; Geriatric Assess | 2019 |
Taking metformin and cognitive function change in older patients with diabetes.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Cognition; Cognitive Dysfunction; Correlation o | 2019 |
Metformin reverses the schizophrenia-like behaviors induced by MK-801 in rats.
Topics: Animals; Antipsychotic Agents; Anxiety; Behavior, Animal; Cognition Disorders; Cognitive Dysfunction | 2019 |
The protective effect of metformin in scopolamine-induced learning and memory impairment in rats.
Topics: Adenylate Kinase; Animals; Antioxidants; Cognitive Dysfunction; Cyclic AMP Response Element-Binding | 2019 |
Dipeptidyl peptidase-4 inhibitors have protective effect on cognitive impairment in aged diabetic patients with mild cognitive impairment.
Topics: Aged; Blood Glucose; Body Mass Index; Cognition; Cognitive Dysfunction; Diabetes Mellitus, Type 2; D | 2014 |
Metformin Use and Cognitive Dysfunction Among Patients with Diabetes Mellitus.
Topics: Cognitive Dysfunction; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin | 2016 |
Metformin Attenuates Cognitive Impairments in Hypoxia-Ischemia Neonatal Rats via Improving Remyelination.
Topics: Animals; Animals, Newborn; Cognitive Dysfunction; Hypoxia-Ischemia, Brain; Maze Learning; Metformin; | 2017 |
Subchronic metformin pretreatment enhances novel object recognition memory task in forebrain ischemia: behavioural, molecular, and electrophysiological studies.
Topics: AMP-Activated Protein Kinases; Animals; Brain Ischemia; Cognitive Dysfunction; Cyclic AMP Response E | 2017 |